Search
for
Sort by
Research 91–120 of 777
- Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness Analysis
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Janus Kinase inhibitors in dermatology: a review
- JAK Inhibitors for Treatment of Alopecia Areata
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Under Development JAK Inhibitors for Dermatologic Diseases
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- JAK inhibitors in dermatology: The promise of a new drug class
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
- Janus kinase inhibitors for alopecia areata: A narrative review
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients